Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

Autor: Einsele H; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany., Moreau P; Hematology Clinic, University Hospital Hotel-Dieu, Nantes, France., Bahlis N; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada., Bhutani M; Atrium Health Levine Cancer Institute/Wake Forest School of Medicine, Winston-Salem, NC, USA., Vincent L; Département d'hématologie Clinique, Centre Hospitalier Universitaire de Montpellier, Montpellier, France., Karlin L; Centre Hospitalier Lyon, Sud, France., Perrot A; Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Goldschmidt H; Medizinische Klinik V, Universitätsklinikum Heidelberg and Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany., van de Donk NWCJ; Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Ocio EM; Hospital Universitario Marqués de Valdecilla (IDIVAL) Universidad de Cantabria, Santander, Spain., Martinez-Lopez J; Hematología Hospital 12 de Octubre, Complutense University, CNIO, i+12, CIBERONC, Madrid, Spain., Rodríguez-Otero P; CIMA, CIBERONC, IDISNA, Clínica Universidad de Navarra, Pamplona, Spain., Dytfeld D; Poznan University of Medical Sciences, Poznan, Poland., Diels J; Janssen Pharmaceutica NV, Beerse, Belgium., Strulev V; Janssen Pharmaceutica NV, Beerse, Belgium., Haddad I; Janssen-Cilag, Issy-les-Moulineaux, France., Renaud T; Johnson & Johnson Innovative Medicine, Raritan, NJ, USA., Ammann E; Janssen Global Services, Raritan, NJ, USA., Cabrieto J; Janssen Pharmaceutica NV, Beerse, Belgium., Perualila N; Janssen Pharmaceutica NV, Beerse, Belgium., Gan R; Johnson & Johnson Innovative Medicine, Brisbane, CA, USA., Zhang Y; Johnson & Johnson Innovative Medicine, Raritan, NJ, USA., Parekh T; Johnson & Johnson Innovative Medicine, Bridgewater, NJ, USA., Albrecht C; Janssen-Cilag, Issy-les-Moulineaux, France., Weisel K; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Mateos MV; University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Paseo de San Vincente, 58-182, 37007, Salamanca, Spain. mvmateos@usal.es.

Publikováno v: Advances in therapy [Adv Ther] 2024 Apr; Vol. 41 (4), pp. 1576-1593. Date of Electronic Publication: 2024 Feb 24.

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.

Autor: Mateos MV; University Hospital of Salamanca/IBSAL, CIC, Salamanca. mvmateos@usal.es., Weisel K; University Medical Center Hamburg-Eppendorf, Hamburg., Martin T; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Berdeja JG; Sarah Cannon Research Institute, Nashville, TN., Jakubowiak A; University of Chicago., Stewart AK; University Health Network and the Princess Margaret Cancer Centre, Toronto, ON., Jagannath S; Mount Sinai Medical Center., Lin Y; Mayo Clinic, Rochester, MN., Diels J; Janssen Pharmaceutica NV, Beerse., Ghilotti F; Janssen-Cilag SpA, Cologno Monzese., Thilakarathne P; Janssen Pharmaceutica NV, Beerse., Perualila NJ; Janssen Pharmaceutica NV, Beerse., Cabrieto J; Janssen Pharmaceutica NV, Beerse., Haefliger B; Cilag GmbH International, Zug., Erler-Yates N; Janssen-Cilag GmbH, Neuss., Hague C; Janssen-Cilag N.V., High Wycombe., Jackson CC; Janssen R-D, Raritan, NJ., Schecter JM; Janssen R-D, Raritan, NJ., Strulev V; EMEA Medical Affairs, Janssen Pharmaceutica NV, Beerse., Nesheiwat T; Legend Biotech USA Inc., Piscataway, NJ., Pacaud L; Legend Biotech USA Inc., Piscataway, NJ., Einsele H; UniversitätsklinikumWürzburg, Medizinische Klinik und Poliklinik II, Würzburg., Moreau P; ClinicalHematology, University Hospital Hotel-Dieu, Nantes.

Publikováno v: Haematologica [Haematologica] 2023 Aug 01; Vol. 108 (8), pp. 2192-2204. Date of Electronic Publication: 2023 Aug 01.

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.

Autor: Chouaid C; Service de Pneumologie, Pneumology, Intercommunal Hospital, 40 avenue de Verdun, 94010, Créteil, France. christos.chouaid@chicreteil.fr., Bosquet L; Health Data and Partnerships Department, Unicancer, Paris, France., Girard N; Institut Curie, Paris, France., Kron A; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.; Network Genomic Medicine, Cologne, Germany.; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.; Network Genomic Medicine, Cologne, Germany.; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Griesinger F; Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, University Medicine Oldenburg, Oldenburg, Germany., Sebastian M; Department of Medicine, Hematology and Oncology, University of Frankfurt, Frankfurt, Germany., Trigo J; Hospital Universitario Virgen de la Victoria y Regional, IBIMA, Malaga, Spain., Viteri S; UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, Spain.; Instituto Oncológico Dr Rosell, Hospital Universitari Dexeus, Grupo QuironSalud, Barcelona, Spain., Knott C; Health Data Insight CIC, Cambridge, UK.; National Disease Registration Service, NHS Digital, Leeds, UK., Rodrigues B; Janssen Cilag, Porto Salvo, Portugal., Rahhali N; Janssen Cilag, Île-de-France, France., Cabrieto J; Janssen Pharmaceutica NV, Beerse, Belgium., Diels J; Janssen Pharmaceutica NV, Beerse, Belgium., Perualila NJ; Janssen Pharmaceutica NV, Beerse, Belgium., Schioppa CA; Janssen Pharmaceutica NV, Beerse, Belgium., Sermon J; Janssen Pharmaceutica NV, Beerse, Belgium., Toueg R; Janssen Cilag, Île-de-France, France., Erdmann N; Janssen-Cilag GmbH, Neuss, Germany., Mielke J; Janssen-Cilag GmbH, Neuss, Germany., Nematian-Samani M; Janssen-Cilag GmbH, Neuss, Germany., Martin-Fernandez C; Janssen-Cilag Ltd, High Wycombe, UK., Pfaira I; Janssen-Cilag Ltd, High Wycombe, UK., Li T; Janssen R&D, Raritan, NJ, USA., Mahadevia P; Janssen R&D, Raritan, NJ, USA., Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.; Network Genomic Medicine, Cologne, Germany.

Publikováno v: Advances in therapy [Adv Ther] 2023 Mar; Vol. 40 (3), pp. 1187-1203. Date of Electronic Publication: 2023 Jan 18.

CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Autor: Chouaid, C, Girard, N, Kron, A, Scheffler, M, Knott, C, Bosquet, L, Trigo, J, Viteri, S, Sebastian, M, Popat, S, Rahhali, N, Toueg, R, Rodrigues, B, Diels, J, Schioppa, CA, Cabrieto, J, Sermon, J, Perualila, NJ, Erdmann, N, Mielke, J, Nematian-Samani, M, Pfaira, I, Martin-Fernandez, C, Mahadevia, P, Li, T, Pick-Lauer, C, Adamczyk, A, Penton, J, Wolf, J

Publikováno v: In Value in Health December 2022 25(12) Supplement:S32-S32

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.

Autor: Merz M; Cell Therapy and Hemostaseology, Department of Hematology, University Hospital of Leipzig, 04103 Leipzig, Germany., Goldschmidt H; Internal Medicine V and National Center for Tumor Diseases, University Clinic Heidelberg, 69120 Heidelberg, Germany., Hari P; Medical College of Wisconsin, Milwaukee, WI 53226, USA., Agha M; School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA., Diels J; Janssen Pharmaceutica NV, 2340 Beerse, Belgium., Ghilotti F; Janssen-Cilag SpA, 20093 Cologno Monzese, Italy., Perualila NJ; Janssen Pharmaceutica NV, 2340 Beerse, Belgium., Cabrieto J; Janssen Pharmaceutica NV, 2340 Beerse, Belgium., Haefliger B; Cilag GmbH International, 6300 Zug, Switzerland., Sliwka H; Janssen-Cilag Pharma GmbH, 1020 Vienna, Austria., Schecter JM; Janssen R&D, Raritan, NJ 08869, USA., Jackson CC; Janssen R&D, Raritan, NJ 08869, USA., Olyslager Y; Janssen Pharmaceutica NV, 2340 Beerse, Belgium., Akram M; Legend Biotech USA, Inc., Piscataway, NJ 08854, USA., Nesheiwat T; Legend Biotech USA, Inc., Piscataway, NJ 08854, USA., Kellermann L; Oncology Information Service (O.I.S), 79098 Freiburg, Germany., Jagannath S; Mount Sinai Medical Center, New York, NY 10029, USA.

Publikováno v: Cancers [Cancers (Basel)] 2021 Nov 29; Vol. 13 (23). Date of Electronic Publication: 2021 Nov 29.